Laduviglusib trihydrochloride

SKU: orb1704618

Description

Laduviglusib trihydrochloride (CT99021 trihydrochloride) is a potent and selective GSK-3 inhibitor, activating Wnt/β-catenin signaling and inducing autophagy. It is widely used in research areas such as neurodegenerative diseases, cancer, and diabetes, with applications in both cellular and animal model studies to investigate related pathways.

Research Area

Cell Biology, Signal Transduction, Stem Cell & Developmental Biology

Images & Validation

−

Key Properties

−

CAS Number	1782235-14-6
MW	573.71
Purity	99.03% (May vary between batches)
Formula	C₂₂H₂₀Cl₅N₈
SMILES	Cl.Cl.Cl.Cc1cnc([nH]1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl
Target	GSK-3,Autophagy,Wnt/beta-catenin
Solubility	H2O:17.1 mg/mL (29.81 mM);DMSO:28.8 mg/mL (50.2 mM);10% DMSO+40% PEG300+5% Tween-80+45% Saline:2 mg/mL (3.49 mM)

Bioactivity

−

Target IC50	CDC2:8800 nM\|GSK-3α:10 nM\|GSK-3β:6.7 nM
In Vivo	Oral administration of Laduviglusib trihydrochloride(16 mg/kg and 48 mg/kg) rapidly reduces plasma glucose with a maximal reduction of nearly 150 mg/dl in ZDF rats. Laduviglusib trihydrochloride enhances mouse and human embryonic stem cells self-renewal. Laduviglusib trihydrochloride (2 mg/kg) improves survival after 14.5 Gy abdominal irradiation. Laduviglusib trihydrochloride inhibits crypt apoptosis and accumulation of p-H2AX+ cells, and improves crypt regeneration and villus height. Laduviglusib trihydrochloride blocks apoptosis, increases Lgr5+ cell survival and prevents the reduction of Olfm4, Lgr5 and CD44.
In Vitro	Laduviglusib trihydrochloride(10 μM) lowers the viability of the ES-D3 cells by 24.7% at 2.5 μM, 56.3% at 5 μM, 61.9% at 7.5 μM and 69.2% with an IC50 of 4.9 μM. Laduviglusib trihydrochloride shows >500-fold selectivity over ERK2, CDC2, and other protein kinases. Laduviglusib trihydrochloride specifically inhibits GSK3β and GSK3α with IC50s of 5nM and 10nM in vitro kinase assays.

Storage & Handling

−

Storage	-20°C
Expiration Date	12 months from date of receipt.
Disclaimer	For research use only

Alternative Names

−

GSK-3α, GSK3, GSK-3β, Laduviglusib, Laduviglusib Trihydrochloride, 252917-06-9, 252917-06-9 free base, bcatenin, beta-catenin, CHIR 99021, CHIR 99021 Trihydrochloride, CHIR 99021 trihydrochloride, CHIR 99021 trihydrochloride (252917-06-9 free base), CHIR99021 Trihydrochloride, CHIR-99021 Trihydrochloride, CHIR99021, CHIR-99021, betacatenin, CT99021 trihydrochloride, CT99021 Trihydrochloride, CT-99021 Trihydrochloride, CT99021, CT-99021, CT 99021, CT 99021 Trihydrochloride, βcatenin, Wnt, Wnt/b-catenin, Wnt/betacatenin, Wnt/β-catenin, Wnt/beta-catenin

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Compound Identifiers

PubChem CID

78243722 ↗

Key Properties

−

No computed properties available.

Protocol Information

Find More Protocols

Purity:	>98%
CAS Number:	1782235-14-6
MW:	574.7207
Formula:	C₂₂H₂₁CL₅N₈

Laduviglusib trihydrochloride

Description

Research Area

Images & Validation

Key Properties

Bioactivity

Storage & Handling

Alternative Names

Similar Products